Peroxisome proliferator-activated receptor g (PPARg) is widely expressed at low levels and regulates many physiological processes. In mice and humans, there is evidence that PPARg can function as a tumor suppressor. A PAX8-PPARg fusion protein (PPFP) is oncogenic in a subset of thyroid cancers, suggesting that inhibition of endogenous PPARg function by the fusion protein could contribute to thyroid oncogenesis. However, the function of PPARg within thyrocytes has never been directly tested. Therefore, we have created a thyroid-specific genetic knockout of murine Pparg and have studied thyroid biology in these mice. Thyroid size and histology, the expression of thyroid-specific genes, and serum T4 levels all are unaffected by loss of thyroidal PPARg expression. PPFP thyroid cancers have increased activation of AKT, and mice with thyroidspecific expression of PPFP combined with thyroid-specific loss of PTEN (a negative regulator of AKT) develop thyroid cancer. Therefore we created mice with combined thyroid-specific deletions of Pparg and Pten to test if there is oncogenic synergy between these deletions. Pten deletion alone results in benign thyroid hyperplasia, and this is unchanged when combined with deletion of Pparg. We conclude that, at least in the contexts studied, thyrocyte PPARg does not play a significant role in the development or function of the thyroid and does not function as a tumor suppressor.
P eroxisome proliferator-activated receptor g (PPARg) is a nuclear receptor transcription factor that regulates adipogenesis, insulin sensitivity, and immune function, but it is widely expressed at low levels and has been shown to regulate numerous other physiological processes. For example, there is evidence in mice and humans that PPARg can function as a tumor suppressor in colon and other cancers (1) (2) (3) (4) (5) . In fact, in a mouse model of thyroid cancer due to mutation of thyroid hormone receptor b, whole-animal deletion of one Pparg allele results in more aggressive disease (6) . A chromosomal translocation results in expression of a PAX8-PPARg fusion protein (PPFP) in a subset of human thyroid cancers, raising the possibility that inhibition of endogenous PPARg may underlie the oncogenic nature of PPFP (7) . However, PPARg is expressed at very low levels in the normal thyroid, and its function in that organ has never been directly examined. Therefore, we have created mice with thyroid-specific, homozygous deletion of Pparg, as well as mice with combined thyroid-specific homozygous deletions of Pparg and Pten. Pten encodes a critical negative regulator of AKT signaling, and increased AKT signaling by loss of PTEN expression or other mechanisms is associated with an increased risk of thyroid cancer (8) (9) (10) . In the contexts studied, we were unable to identify a role for thyrocyte PPARg in the development or function of the mouse thyroid, and PPARg did not function as a tumor suppressor.
Materials and Methods

Mouse breeding and genotyping
All protocols were approved by the University of Michigan Institutional Animal Care and Use Committee. Floxed Pparg mice were obtained from the Jackson Laboratory (Bar Harbor, ME) (Pparg tm2Rev /J; stock no. 004584). Floxed Pten mice (8, 11) and transgenic mice in which Cre recombinase expression is driven by the human thyroid peroxidase (TPO) promoter are as described (12, 13) . All mice were bred on a pure FVB/N background. Breeding between these mice yielded progeny that were hemizygous for TPO-Cre and homozygous for floxed Pparg, resulting in homozygous thyroid-specific deletion of Pparg (hereafter denoted Pparg Thy2/2 ). Littermate homozygous floxed Pparg mice lacking Cre (Pparg F/F ) were used as controls. ) and mice with homozygous thyroid-specific deletion of just Pten (Pten Thy2/2 ) that served as controls. Both male and female mice were studied. Genotyping was performed on tail DNA for Cre and the floxed Pten allele as previously described (8, 13) and for the floxed Pparg allele as described on the Jackson Laboratory website (https://www.jax.org/strain/ 004584). Thyroid gland genomic DNA was isolated using the Wizard SV Genomic DNA Purification System (Promega, Madison, WI) and was used to confirm Cre-mediated deletion of Pparg. We have previously confirmed the excision of floxed Pten by TPO promoter-Cre expression in mouse thyroid glands (8) . Polymerase chain reaction (PCR) primers are listed in Table 1 .
Thyroid histology and real-time reverse transcription PCR
The right lobes of the mouse thyroid glands were removed en bloc with the trachea and fixed in 10% formalin, and 5-m sections were stained with hematoxylin and eosin. The left lobes of the thyroid glands were isolated, weighed, and used to prepare total RNA with a Qiagen RNeasy mini kit (Qiagen, Inc., Germantown, MD). The RNA was reverse transcribed using random hexamer primers and Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA). The complementary DNA was analyzed by real-time PCR on an Applied Biosystems (Foster City, CA) Step One Plus instrument using PowerUp SYBR ® Green Master Mix (ThermoFisher Scientific, Waltham, MA). Each 20-mL PCR reaction used the complementary DNA from 75 ng total RNA, except the reactions for thyroglobulin and thyroid peroxidase used 1% of that amount. PCR primers are listed in Table 1 .
Thyroid ultrasound
Ultrasound images were recorded using a VisualSonics Vevo 2100 high-resolution microimaging system with a MS 550D transducer (VisualSonics, Toronto, Canada). The largest cross-sectional area of each thyroid lobe was estimated using the formula for the area of an ellipse and the long and short axes dimensions of the lobe.
Serum thyroxine
Serum thyroxine levels were measured using the AccuDiag T4 ELISA Kit (catalog no. 3149-16) from Diagnostic Automation/ Cortex Diagnostics, Inc. (Woodland Hills, CA).
Statistical analysis
Comparisons were by analysis of variance followed by the Newman-Keuls test, with P , 0.05 considered significant. Because there were no differences between males and females, both sexes were combined for comparisons between genotypes. Twelve mice were studied for each genotype (six male, six female).
Results
Successful excision of Pparg in the mouse thyroid
Genomic DNA was isolated from the thyroid glands of Pparg Thy2/2 and Pparg F/F mice. Analysis by PCR demonstrated essentially complete Cre-mediated excision of Pparg in Pparg Thy2/2 mice ( Fig. 1 ).
Thyroid biology in the absence of PPARg As shown in Fig. 2A (left two bars), there was no difference in the cross-sectional areas of the thyroid glands in Pparg Thy2/2 mice compared with Pparg F/F mice, and this similarity was confirmed by finding no difference in the weights of the left thyroid lobes (Fig. 2B , left two bars) (the right lobes were fixed in formalin en bloc with the tracheas and therefore were not weighed). Histologically, the thyroid glands of Pparg Thy2/2 and 
GGAGGGGGATTTCACCACAC GAGGACCCTGGATCCACTTG
Abbreviations: NIS, sodium iodide symporter; TTF-1, thyroid transcription factor 1. a TPO-Cre genotyping utilizes a three-primer PCR so that the wild-type and transgene alleles are both detected (379 and 332 bp, respectively) (13).
b All real-time PCR amplicons are intron spanning.
Pparg F/F mice also were similar (Fig. 2C , left two panels). To further evaluate potential effects of loss of PPARg on thyroid function, we used real-time reverse transcription-PCR to measure the expression of five genes that are critical to normal thyroid function: Tg, Tpo, Duox2, Nkx2-1 (thyroid transcription factor 1), and Slc5a5 (sodium iodide symporter), as well as Pgk1 as a housekeeping gene. None of these genes differed in expression between Pparg Thy2/2 and Pparg F/F mice (Fig. 2D , left two bars for each gene). Previous RNA-seq and chromatin immunoprecipitation-seq studies of a transgenic mouse model of PPFP thyroid cancer identified genes that are induced by PPFP and that contain PPFP chromatin immunoprecipitation-seq peaks with PPARg motifs (14) , suggesting these genes also might be regulated by endogenous PPARg in the normal thyroid. We tested the expression of five such genes: the cell cycle gene Ccnd1 and the lipid metabolism genes Angptl4, Cd36, Fabp4, and Gpd1. However, none of these differed in expression between Pparg Thy2/2 and Pparg F/F mice (Fig. 2E , left two bars for each gene). Furthermore, the serum T4 levels were not statistically different in Pparg Thy2/2 and Pparg F/F mice (Fig. 2F, left two bars) . Thus, at least based on these criteria, loss of PPARg expression within the thyroid gland has no discernable effect on thyroid development or function.
Lack of synergy between deletion of Pparg and deletion of Pten
There is evidence that Pparg can function as a tumor suppressor gene (1-6). Although we found there was no thyroid neoplasia with simple deletion of Pparg within the thyroid, the potential exists that loss of PPARg may synergize with other factors in thyroid neoplasia. We decided to test for an interaction between thyroid-specific deletions of Pparg and Pten for several reasons. In humans, loss-of-function mutations in PTEN cause Cowden syndrome, which is associated with an increased risk of thyroid cancer (9) . In FVB/N mice, homozygous deletion of Pten causes benign hyperplasia without neoplasia (8) . However, Pten deletion synergizes with thyroid-specific expression of PPFP to cause metastatic thyroid cancer in mice (8) . This is consistent with data from patients with PPFP thyroid cancer because they also manifest increased activation (phosphorylation) of AKT (15) , and PTEN is a negative regulator of AKT signaling. Thus, a reasonable hypothesis is that the combined deletions of Pparg and Pten might phenocopy the oncogenic effect of PPFP expression combined with Pten deletion. Fig. 2A , right three bars) and weight (Fig. 2B, right three bars) . Although the increase in thyroid weight was statistically slightly greater in Pparg Thy2/2 ;Pten Thy2/2 mice than Pten Thy2/2 mice, this is unlikely to be biologically important because there was no difference in thyroid area between these genotypes or in the other parameters described below. As reported previously (8) , Pten Thy2/2 thyroids have benign hyperplasia, and here we show that there were no further histological changes in the Pparg Thy2/2 ;Pten Thy2/2 mice (Fig. 2C, right ;Pten Thy2/2 mice (Fig. 2D , right three bars for each gene). Similarly, Pten deletion was associated with decreased thyroidal expression of Angptl4, Cd36, Fabp4, and Gpd1, but there were no differences between Pten Thy2/2 and Pparg Thy2/2 ; Pten Thy2/2 mice (Fig. 2E , right three bars for each gene). Finally, Pten deletion was associated with increased serum T4, but there were no further differences between Pten Thy2/2 and Pparg Thy2/2 ;Pten Thy2/2 mice (Fig. 2F , right three bars). We conclude that Pten Thy2/2 and Pparg Thy2/2 ;Pten Thy2/2 mice have essentially identical phenotypes, and the genetic deletions of Pparg and Pten do not synergize to cause thyroid neoplasia.
Discussion
PPARg is the master regulator of adipogenesis (16) and was subsequently found to regulate insulin sensitivity Figure 1 . Cre-mediated deletion of Pparg in the mouse thyroid. Thyroid DNA was isolated from Pparg Thy2/2 and Pparg F/F mice and subjected to PCR to detect Cre-mediated excision of the first two coding exons of PPARg1. The expected band is 0.8 kb after Cremediated excision and 4 kb in the absence of excision.
when it was discovered to be the target of thiazolidinediones, which are used to treat type 2 diabetes (17). Over time, there has been increased appreciation of low-level PPARg expression in many cell types, and genetic deletion experiments in mice have revealed roles for PPARg in, for example, vascular smooth muscle cells (18), macrophages (19) , T cells (20) , hair follicle stem cells (21) , neurons (22, 23) , and hepatocytes (24) . Furthermore, several lines of evidence suggest PPARg may have tumor-suppressive properties (1) (2) (3) (4) (5) . For example, in a mouse model of thyroid cancer due to mutation of thyroid hormone receptor b, the cancer is more aggressive when combined with single-allele whole-mouse deletion of Pparg (6) . A subset of thyroid cancers is caused by a chromosomal translocation that results in production of PPFP, suggesting that disruption of endogenous PPARg function could be part of the oncogenic mechanism (7). However, the function of PPARg within the thyroid gland has not previously been directly studied.
Here, we show that thyroid-specific genetic deletion of Pparg in mice has no effect on thyroid development or function in the basal state. Thyroid size and histology, the expression of thyroid differentiation genes, and serum T4 levels all are unaffected by deletion of Pparg (Fig. 2) . Even genes that are likely induced by PPFP via PPARg binding sites in a mouse model of thyroid cancer (14) have unaltered expression in mice lacking thyroidal PPARg (Fig. 2E) . This is probably due to the fact that PPFP is expressed at high levels in thyroid cancer, but PPARg is expressed at very low levels in the normal thyroid. It should be noted that the TPO promoter that drives Cre expression becomes active at embryonic day 14.5 (12) , and therefore the current studies do not address whether PPARg could play a role earlier in thyroid development. We also found no evidence for a role for endogenous PPARg as a thyroid tumor suppressor, either by itself or in concert with loss of PTEN.
How can one square these findings with the observation that single-allele deletion of Pparg in mice enhances the oncogenic action of the "PV" mutation in thyroid hormone receptor b (6)? One possibility is that endogenous PPARg is relevant only in certain types of thyroid cancer. It should be noted that the PV mutation results in severe thyroid hormone resistance with high levels of thyrotropin, thus activating cyclic adenosine monophosphate and potentially other pathways not activated in our mice. Alternatively, it should be noted that the previously described synergy is in the context of a whole-mouse deletion of Pparg, and it may be that the critical cell type for loss of PPARg expression is not the thyrocyte but, for example, could be immune cells, vascular cells, or other cell types.
In addition, differences in genetic background or age of the mice could play a role. The consequences of Pten deletion in the mouse thyroid are strain dependent (25) . Furthermore, thyroid cancer due to Pten deletion by itself may take 1 to 2 years to manifest, whereas our mice were studied at 6 to 7 months of age (26) .
In conclusion, we found no evidence of a role for PPARg in the development or function of the mouse thyroid gland or evidence that thyroidal PPARg functions as a tumor suppressor. However, it remains possible that PPARg could play an important role early in thyroid development (prior to mouse embryonic day 14.5), in other models of thyroid cancer, or under stressful circumstances such as iodine deficiency.
